XX-650-23

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562227

CAS#: 117739-40-9

Description: XX-650-23 is an inhibitor of CREB (cAMP Response Element Binding protein).


Price and Availability

Size
Price

Size
Price

Size
Price

XX-650-23 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 562227
Name: XX-650-23
CAS#: 117739-40-9
Chemical Formula: C18H12N2O2
Exact Mass: 288.0899
Molecular Weight: 288.3
Elemental Analysis: C, 74.99; H, 4.20; N, 9.72; O, 11.10


Synonym: XX-650-23; XX 650 23; XX65023;

IUPAC/Chemical Name: N-(4-Cyanophenyl)-3-hydroxy-2-naphthamide

InChi Key: DRBIYQSSEMTUJQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H12N2O2/c19-11-12-5-7-15(8-6-12)20-18(22)16-9-13-3-1-2-4-14(13)10-17(16)21/h1-10,21H,(H,20,22)

SMILES Code: O=C(NC1=CC=C(C#N)C=C1)C2=C(O)C=C3C=CC=CC3=C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capolicchio S, Smith M, Sakamoto KM. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget. 2017 Dec 31;9(4):4301-4317. doi: 10.18632/oncotarget.23794. eCollection 2018 Jan 12. PubMed PMID: 29435104; PubMed Central PMCID: PMC5796975.

2: François S, Sen N, Mitton B, Xiao X, Sakamoto KM, Arvin A. Varicella-Zoster Virus Activates CREB, and Inhibition of the pCREB-p300/CBP Interaction Inhibits Viral Replication In Vitro and Skin Pathogenesis In Vivo. J Virol. 2016 Sep 12;90(19):8686-97. doi: 10.1128/JVI.00920-16. Print 2016 Oct 1. PubMed PMID: 27440893; PubMed Central PMCID: PMC5021407.

3: Mitton B, Chae HD, Hsu K, Dutta R, Aldana-Masangkay G, Ferrari R, Davis K, Tiu BC, Kaul A, Lacayo N, Dahl G, Xie F, Li BX, Breese MR, Landaw EM, Nolan G, Pellegrini M, Romanov S, Xiao X, Sakamoto KM. Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells. Leukemia. 2016 Dec;30(12):2302-2311. doi: 10.1038/leu.2016.139. Epub 2016 May 23. PubMed PMID: 27211267; PubMed Central PMCID: PMC5143163.